CAR-T therapies targeting CD19, namely axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), and lisocabtagene maraleucel (liso-cel), have transformed the management of R/R DLBCL in fit patients. Here, CD19 is linked to diffuse large B-cell lymphoma.